A retrospective study of vedolizumab versus adalimumab, golimumab, and infliximab in biologics-naïve patients with inflammatory bowel disease treated in gastroenterological practices and outpatient clinics in Germany
Latest Information Update: 20 Jul 2021
Price :
$35 *
At a glance
- Drugs Vedolizumab (Primary) ; Adalimumab; Golimumab; Infliximab
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
- 20 Jul 2021 New trial record